Search Results - "YOSHIHARA, Kazutaka"

Clinical Pharmacokinetics of Laninamivir, a Novel Long-Acting Neuraminidase Inhibitor, After Single and Multiple Inhaled Doses of Its Prodrug, CS-8958, in Healthy Male Volunteers by Ishizuka, Hitoshi, Yoshiba, Satoshi, Okabe, Hiromi, Yoshihara, Kazutaka

“…Phase 1 studies of laninamivir, a novel long‐acting neuraminidase inhibitor, were carried out to assess its safety, tolerability, and pharmacokinetics after…”
Get full text

Safety and Pharmacokinetics of DS-8500a, a Novel GPR119 Agonist, After Multiple Oral Doses in Healthy Japanese Males by Kato, Manabu, Furuie, Hidetoshi, Kamiyama, Emi, Shiosakai, Kazuhito, Yoshihara, Kazutaka, Taguchi, Takashi

“…Background and objectives G protein-coupled receptor 119 (GPR119) agonists reduce plasma glucose by promoting insulin secretion in a glucose-dependent manner…”
Get full text

Assessment of the Effects of Renal Impairment on the Pharmacokinetic Profile of Laninamivir, a Novel Neuraminidase Inhibitor, After a Single Inhaled Dose of Its Prodrug, CS-8958 by Ishizuka, Hitoshi, Yoshiba, Satoshi, Yoshihara, Kazutaka, Okabe, Hiromi

“…This open‐label, single‐dose study assessed the safety and pharmacokinetics of laninamivir, a new long‐acting neuraminidase inhibitor, after an inhaled 20‐mg…”
Get full text

Population Pharmacokinetics of Laninamivir and Its Prodrug Laninamivir Octanoate in Healthy Subjects and in Adult and Pediatric Patients with Influenza Virus Infection by Yoshihara, Kazutaka, Ishizuka, Hitoshi, Kubo, Yuichi

“…Laninamivir octanoate (LO) is a new neuraminidase inhibitor for inhalation. The objectives of this study were to model the population pharmacokinetics of LO…”
Get full text

Association study of genetic polymorphisms of drug transporters, SLCO1B1, SLCO1B3 and ABCC2, in African-Americans, Hispanics and Caucasians and olmesartan exposure by Endo, Seiko, Fukahori, Aiko, Tokuhiro, Shinya, Shinagawa, Akira, Walker, Joseph, Yoshihara, Kazutaka, Ishizuka, Hitoshi, Ieiri, Ichiro, Sugiyama, Yuichi

“…It has been reported that organic anion-transporting polypeptide (OATP) 1B1, OATP1B3 and multidrug resistance-associated protein 2 are involved in the…”
Get full text

Comparative Pharmacodynamics of Olmesartan and Azelnidipine in Patients with Hypertension: a Population Pharmacokinetic/Pharmacodynamic Analysis by Tanigawara, Yusuke, Yoshihara, Kazutaka, Kuramoto, Kizuku, Arakawa, Kikuo

“…The objectives of this study were to identify the factors influencing antihypertensive response to the angiotensin receptor blocker, olmesartan medoxomil, or…”
Get full text

Population Pharmacokinetics of Laninamivir and Its Prodrug Laninamivir Octanoate in Healthy Subjects and in Adult and Pediatric Patients with Influenza Virus Infection by Kazutaka YOSHIHARA, Hitoshi ISHIZUKA, Yuichi KUBO

“…[Summary]: Laninamivir octanoate (LO) is a new neuraminidase inhibitor for inhalation. The objectives of this study were to model the population…”
Get full text

Population Pharmacokinetics of Trastuzumab Deruxtecan in Patients With HER2‐Positive Breast Cancer and Other Solid Tumors by Yin, Ophelia, Xiong, Yuan, Endo, Seiko, Yoshihara, Kazutaka, Garimella, Tushar, AbuTarif, Malaz, Wada, Russ, LaCreta, Frank

“…Trastuzumab deruxtecan (DS‐8201) is a human epidermal growth factor receptor 2 (HER2)–targeting antibody–drug conjugate with a novel enzyme‐cleavable linker, a…”
Get full text

Exposure-response analysis of the efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with or without diabetic kidney disease by Yoshihara, Kazutaka, Fukae, Masato, Kastrissios, Helen, Wada, Russell, Shimizu, Takako

“…Esaxerenone is a novel non-steroidal mineralocorticoid receptor blocker. Here, we assessed efficacy and safety exposure-response relationships of esaxerenone…”
Get full text

Trastuzumab Deruxtecan Dosing in Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer: Population Pharmacokinetic Modeling and Exposure-Response Analysis by Yoshihara, Kazutaka, Kobayashi, Yoshimasa, Endo, Seiko, Fukae, Masato, Hennig, Stefanie, Kastrissios, Helen, Kamiyama, Emi, Garimella, Tushar, Abutarif, Malaz

“…This study evaluated the benefit/risk of trastuzumab deruxtecan (T-DXd) 6.4 mg/kg in patients with human epidermal growth factor receptor 2 (HER2)-positive…”
Get full text

Population pharmacokinetics of esaxerenone, a novel non-steroidal mineralocorticoid receptor blocker, in patients with essential hypertension, patients with diabetic nephropathy, and healthy volunteers by Yoshihara, Kazutaka, Fukae, Masato, Kastrissios, Helen, Wada, Russell, Shimizu, Takako, Ishizuka, Hitoshi

“…Esaxerenone is a novel, non-steroidal mineralocorticoid receptor (MR) blocker with improved selectivity and affinity for MR. The objectives of this study were…”
Get full text

DS-5670a, a novel mRNA-encapsulated lipid nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2: Results from a phase 2 clinical study by Toyama, Kaoru, Eto, Takashi, Takazawa, Kenji, Shimizu, Shinji, Nakayama, Tetsuo, Furihata, Kei, Sogawa, Yoshitaka, Kumazaki, Masafumi, Jonai, Nao, Matsunaga, Satoko, Takeshita, Fumihiko, Yoshihara, Kazutaka, Ishizuka, Hitoshi

“…•DS-5670a, an mRNA vaccine, targets the RBD of the SARS-CoV-2 spike protein.•Immunologically-naïve adults received 2 injections of DS-5670a, 4 weeks…”
Get full text

Comparative Pharmacodynamics of Olmesartan and Azelnidipine in Patients with Hypertension: a Population Pharmacokinetic/Pharmacodynamic Analysis by Yusuke TANIGAWARA, Kazutaka YOSHIHARA, Kizuku KURAMOTO, Kikuo ARAKAWA

“…[Summary]: The objectives of this study were to identify the factors influencing antihypertensive response to the angiotensin receptor blocker, olmesartan…”
Get full text

Abstract 5049: Application of population pharmacokinetic and exposure-response modeling for DS-8201a, a HER2-targeting ADC, predicts 50% ORR in patients with heavily pretreated breast cancer by Yoshihara, Kazutaka, Endo, Seiko, Tamura, Kenji, Doi, Toshihiko, Tokui, Taro

“…Background: Antibody-drug conjugates (ADC) provide a wider therapeutic index by allowing specific targeting of cytotoxic agents to tumor cells. DS-8201a is a…”
Get full text

Pharmacokinetics and Bioequivalence of Mirogabalin Orally Disintegrating Tablets and Conventional Tablets in Healthy Japanese Participants by Toyama, Kaoru, Eto, Takashi, Suzuki, Kanae, Shinohara, Sayaka, Yoshiba, Satoshi, Yoshihara, Kazutaka, Ishizuka, Hitoshi

“…This single-center, randomized, open-label, single-dose, 2-group, 2-stage crossover trial evaluated the bioequivalence of 15 mg of mirogabalin as orally…”
Get full text

Population Pharmacokinetics of Edoxaban in Japanese Atrial Fibrillation Patients With Severe Renal Impairment by Shimizu, Takako, Tachibana, Masaya, Kimura, Tetsuya, Kumakura, Tomohiko, Yoshihara, Kazutaka

“…This is a population pharmacokinetic (PopPK) analysis to predict PK of edoxaban, a direct‐acting oral anticoagulant, in nonvalvular atrial fibrillation (NVAF)…”
Get full text

Population Pharmacokinetic and Exposure-Response Modeling for the EZH1/2 Dual Inhibitor DS-3201b in Patients with Non-Hodgkin Lymphomas by Atsumi, Ryo, Yoshiba, Satoshi, Maruyama, Dai, Tobinai, Kensei, Ishida, Takashi, Ishitsuka, Kenji, Imaizumi, Yoshitaka, Takeuchi, Shogo, Tsukasaki, Kunihiro, Adachi, Nobuaki, Fujitani, Sumiaki, Tachibana, Masaya, Yoshihara, Kazutaka, Ishizuka, Hitoshi

“…▪ Introduction: Epigenetic regulators are an emerging new target class for cancer therapy. Enhancer of zeste homolog 1 (EZH1) and EZH2 are alternative subunits…”
Get full text

Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil : In healthy volunteers and hypertensive patients by YOSHIHARA, Kazutaka, YUYING GAO, SHIGA, Hiroshi, WADA, D. Russell, HISAOKA, Masafumi

“…Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype. To develop a…”
Get full text